Catalyst Biosciences IncNASDAQ:CBIONASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.2950
- TODAY'S CHANGE (%)-0.0091 (-2.9924%)
- Bid / Lots0.2900/ 27
- Ask / Lots0.3000/ 1
- Open / Previous Close0.3118 / 0.3041
- Day Range
- 52 Week Range
- Volume577,979
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CBIO |
|---|---|---|
| 09:32 ET | 21235 | 0.310001 |
| 09:33 ET | 100 | 0.315 |
| 09:35 ET | 1800 | 0.3149 |
| 09:37 ET | 5500 | 0.3122 |
| 09:46 ET | 1000 | 0.310101 |
| 09:48 ET | 3000 | 0.3122 |
| 09:51 ET | 7000 | 0.3122 |
| 09:55 ET | 2800 | 0.3122 |
| 10:02 ET | 100 | 0.31 |
| 10:06 ET | 444 | 0.3149 |
| 10:08 ET | 500 | 0.3111 |
| 10:09 ET | 33244 | 0.3149 |
| 10:11 ET | 700 | 0.3148 |
| 10:13 ET | 2400 | 0.315 |
| 10:15 ET | 2200 | 0.3163 |
| 10:18 ET | 1000 | 0.3189 |
| 10:20 ET | 131 | 0.318799 |
| 10:22 ET | 1000 | 0.3161 |
| 10:24 ET | 1600 | 0.3144 |
| 10:27 ET | 10200 | 0.3178 |
| 10:29 ET | 9600 | 0.3178 |
| 10:31 ET | 100 | 0.3177 |
| 10:33 ET | 50300 | 0.32 |
| 10:38 ET | 250 | 0.315049 |
| 10:45 ET | 100 | 0.3101 |
| 10:47 ET | 525 | 0.315 |
| 10:49 ET | 4300 | 0.3149 |
| 10:51 ET | 200 | 0.3102 |
| 10:54 ET | 3000 | 0.315 |
| 10:58 ET | 3351 | 0.310301 |
| 11:00 ET | 150 | 0.315 |
| 11:03 ET | 2065 | 0.31 |
| 11:05 ET | 100 | 0.31 |
| 11:07 ET | 100 | 0.31 |
| 11:09 ET | 500 | 0.3149 |
| 11:12 ET | 100 | 0.31 |
| 11:14 ET | 300 | 0.310563 |
| 11:16 ET | 6001 | 0.3115 |
| 11:18 ET | 844 | 0.3101 |
| 11:20 ET | 100 | 0.31 |
| 11:21 ET | 1155 | 0.3101 |
| 11:23 ET | 2100 | 0.31 |
| 11:25 ET | 2199 | 0.3101 |
| 11:30 ET | 200 | 0.31 |
| 11:34 ET | 1902 | 0.3101 |
| 12:03 ET | 5000 | 0.310101 |
| 12:10 ET | 4531 | 0.313 |
| 12:12 ET | 90513 | 0.31 |
| 12:14 ET | 100 | 0.3099 |
| 12:15 ET | 500 | 0.306949 |
| 12:21 ET | 2817 | 0.3099 |
| 12:26 ET | 200 | 0.3099 |
| 12:44 ET | 500 | 0.3067 |
| 12:46 ET | 63351 | 0.3034 |
| 12:48 ET | 9995 | 0.3027 |
| 12:51 ET | 12603 | 0.3057 |
| 12:55 ET | 14264 | 0.31 |
| 12:57 ET | 100 | 0.3099 |
| 01:00 ET | 3932 | 0.3 |
| 01:06 ET | 10240 | 0.3098 |
| 01:08 ET | 5135 | 0.305 |
| 01:11 ET | 135 | 0.304549 |
| 01:24 ET | 1219 | 0.3089 |
| 01:31 ET | 1819 | 0.3079 |
| 01:33 ET | 22600 | 0.309 |
| 01:40 ET | 100 | 0.309 |
| 01:42 ET | 1000 | 0.3001 |
| 01:45 ET | 1500 | 0.301324 |
| 01:49 ET | 6846 | 0.305 |
| 01:51 ET | 500 | 0.305 |
| 01:54 ET | 1300 | 0.305 |
| 02:27 ET | 200 | 0.3022 |
| 02:41 ET | 3809 | 0.3022 |
| 02:54 ET | 8687 | 0.3 |
| 02:57 ET | 100 | 0.3021 |
| 03:03 ET | 400 | 0.3 |
| 03:06 ET | 500 | 0.3017 |
| 03:08 ET | 100 | 0.3017 |
| 03:12 ET | 46480 | 0.3009 |
| 03:14 ET | 3700 | 0.2957 |
| 03:15 ET | 280 | 0.2974 |
| 03:19 ET | 6900 | 0.29 |
| 03:24 ET | 3000 | 0.2945 |
| 03:26 ET | 1201 | 0.295 |
| 03:28 ET | 3000 | 0.2901 |
| 03:32 ET | 1214 | 0.295 |
| 03:33 ET | 630 | 0.2924 |
| 03:35 ET | 7260 | 0.290201 |
| 03:37 ET | 1000 | 0.2902 |
| 03:39 ET | 600 | 0.2902 |
| 03:42 ET | 8000 | 0.294999 |
| 03:44 ET | 2300 | 0.2906 |
| 03:46 ET | 700 | 0.2927 |
| 03:51 ET | 972 | 0.2905 |
| 03:53 ET | 1442 | 0.2906 |
| 03:55 ET | 2802 | 0.2933 |
| 03:57 ET | 965 | 0.2906 |
| 04:00 ET | 6146 | 0.295 |
Jan 26, 2023
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates QUMU, MPB, CBIO, from 1:13PM ET on Thursday Jan 26, 2023 by PR Newswire
1:13PM ET on Thursday Jan 26, 2023 by PR NewswireSHAREHOLDER ALERT: Weiss Law Reminds CBIO, AJRD, SAL, and SHBI Shareholders About Its Ongoing Investigations, from 8:00AM ET on Thursday Jan 26, 2023 by PR Newswire
8:00AM ET on Thursday Jan 26, 2023 by PR Newswire
Jan 19, 2023
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CBIO, HZN, CLXT, VLTA, from 10:50AM ET on Thursday Jan 19, 2023 by PR Newswire
10:50AM ET on Thursday Jan 19, 2023 by PR Newswire
Jan 18, 2023
SHAREHOLDER ALERT: Weiss Law Reminds APEN, HZN, CBIO, and AJRD Shareholders About Its Ongoing Investigations, from 5:00PM ET on Wednesday Jan 18, 2023 by PR Newswire
5:00PM ET on Wednesday Jan 18, 2023 by PR Newswire
Jan 13, 2023
Top Premarket Decliners, from 7:46AM ET on Friday Jan 13, 2023 by MT Newswires
7:46AM ET on Friday Jan 13, 2023 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Catalyst Biosciences Inc | 11.1M | 0.8x | --- |
Kineta Inc | 9.8M | -2.3x | --- |
Bellicum Pharmaceuticals Inc | 10.9M | -2.8x | --- |
Petros Pharmaceuticals Inc | 5.4M | -1.7x | --- |
Talis Biomedical Corp | 15.8M | -0.1x | --- |
International Stem Cell Corp | 1.5M | -2.2x | --- |
Company Information
Catalyst Biosciences, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on protease therapeutics to address unmet medical needs in disorders of the complement and coagulation systems. The Company's product candidates consist of the coagulation-related assets marzeptacog alfa (activated) (MarzAA), dalcinonacog alfa (DalcA), and CB 2679d-GT. The Company's product MarzAA is a subcutaneously (SQ) administered next generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding and prophylaxis in subjects with rare bleeding disorders. The Company's DalcA is a next generation SQ Factor IX product candidate for the prophylactic treatment of individuals with hemophilia B. Its CB 2679d-GT is an Adeno-associated virus (AAV)-based gene therapy construct harboring the DalcA sequence. The Company's SQ product candidates demonstrate a prolonged duration of activity enabling them to provide continuous therapeutic levels.
Contact Information
- Headquarters
- 611 Gateway Blvd Ste 710SOUTH SAN FRANCISCO, CA, United States 94080-7029
- Phone
- 650-871-0761
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Augustine Lawlor
- President, Chief Executive Officer, Director
- Nassim Usman
- Interim Chief Financial Officer, Principal Accounting Officer
- Seline Miller
- Director
- Thomas Eastling
- Director
- Ying Luo
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $11.1M |
|---|---|
Revenue (TTM) | $3.2M |
Shares Outstanding | 37.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.91 |
EPS | $0.38 |
Book Value | $1.31 |
P/E Ratio | 0.8x |
Price/Sales (TTM) | 3.4 |
Price/Cash Flow (TTM) | 0.9x |
Operating Margin | 356.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
